JP2018100276A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018100276A5 JP2018100276A5 JP2018017168A JP2018017168A JP2018100276A5 JP 2018100276 A5 JP2018100276 A5 JP 2018100276A5 JP 2018017168 A JP2018017168 A JP 2018017168A JP 2018017168 A JP2018017168 A JP 2018017168A JP 2018100276 A5 JP2018100276 A5 JP 2018100276A5
- Authority
- JP
- Japan
- Prior art keywords
- methods
- novel articles
- manufacture substantially
- manufacture
- articles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681447P | 2012-08-09 | 2012-08-09 | |
| US61/681,447 | 2012-08-09 | ||
| US201261722727P | 2012-11-05 | 2012-11-05 | |
| US61/722,727 | 2012-11-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526690A Division JP6347782B2 (ja) | 2012-08-09 | 2013-08-08 | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018100276A JP2018100276A (ja) | 2018-06-28 |
| JP2018100276A5 true JP2018100276A5 (OSRAM) | 2018-08-09 |
Family
ID=49004013
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526690A Active JP6347782B2 (ja) | 2012-08-09 | 2013-08-08 | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
| JP2018017168A Withdrawn JP2018100276A (ja) | 2012-08-09 | 2018-02-02 | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526690A Active JP6347782B2 (ja) | 2012-08-09 | 2013-08-08 | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20140045843A1 (OSRAM) |
| EP (2) | EP2882442B1 (OSRAM) |
| JP (2) | JP6347782B2 (OSRAM) |
| KR (3) | KR102146848B1 (OSRAM) |
| CN (4) | CN104837491A (OSRAM) |
| AU (1) | AU2013299627C1 (OSRAM) |
| BR (1) | BR112015002285B1 (OSRAM) |
| CA (1) | CA2881116C (OSRAM) |
| CY (1) | CY1124622T1 (OSRAM) |
| DK (1) | DK2882442T3 (OSRAM) |
| EA (1) | EA029485B1 (OSRAM) |
| ES (1) | ES2881220T3 (OSRAM) |
| HR (1) | HRP20211243T1 (OSRAM) |
| HU (1) | HUE056127T2 (OSRAM) |
| IL (3) | IL288506B2 (OSRAM) |
| IN (1) | IN2015DN00886A (OSRAM) |
| LT (1) | LT2882442T (OSRAM) |
| MX (1) | MX367869B (OSRAM) |
| NI (1) | NI201500012A (OSRAM) |
| NZ (1) | NZ628078A (OSRAM) |
| PH (1) | PH12015500212A1 (OSRAM) |
| PL (1) | PL2882442T3 (OSRAM) |
| PT (1) | PT2882442T (OSRAM) |
| RS (1) | RS62201B1 (OSRAM) |
| SG (3) | SG11201500998QA (OSRAM) |
| SI (1) | SI2882442T1 (OSRAM) |
| SM (1) | SMT202100457T1 (OSRAM) |
| TW (2) | TWI653977B (OSRAM) |
| UA (1) | UA116544C2 (OSRAM) |
| WO (1) | WO2014025960A1 (OSRAM) |
| ZA (1) | ZA201500564B (OSRAM) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120134969A1 (en) | 2009-05-25 | 2012-05-31 | Hiroshi Handa | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| SG10201501062SA (en) | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| JP6042406B2 (ja) | 2011-03-28 | 2016-12-14 | メイ プハルマ，インコーポレーテッド | （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物 |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| CN104797256A (zh) * | 2012-09-10 | 2015-07-22 | 细胞基因公司 | 用于治疗局部晚期乳腺癌的方法 |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| EA201691144A1 (ru) | 2013-12-06 | 2016-11-30 | Селджин Корпорейшн | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка |
| JP6640126B2 (ja) | 2014-06-27 | 2020-02-05 | セルジーン コーポレイション | セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
| JP2017538104A (ja) * | 2014-10-07 | 2017-12-21 | セルジーン コーポレイション | 癌治療に対する臨床的感応性を予測するためのバイオマーカーの使用 |
| JP2018529344A (ja) * | 2015-09-25 | 2018-10-11 | セルジーン コーポレイション | びまん性大細胞型ｂ細胞リンパ腫の治療方法及び薬物に対する応答性の予測因子としてのバイオマーカー利用 |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| KR102002581B1 (ko) * | 2016-10-04 | 2019-07-22 | 주식회사 종근당 | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 |
| US20180238886A1 (en) * | 2017-01-31 | 2018-08-23 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
| MX2019013634A (es) * | 2017-05-16 | 2020-01-21 | Biomed Valley Discoveries Inc | Composiciones y metodos para tratar cancer con mutaciones de braf atipicas. |
| AU2018271862B2 (en) | 2017-05-23 | 2022-12-15 | Mei Pharma, Inc. | Combination therapy |
| SMT202300068T1 (it) * | 2017-06-30 | 2023-03-17 | Celgene Corp | Composizioni e metodi d'uso di 2-(4-clorofenil)-n-((2-(2,6-diossopiperidin-3-il)-1-ossoisoindolin-5-il)metil)-2,2-difluoroacetammide |
| US10357489B2 (en) * | 2017-07-10 | 2019-07-23 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| JP2020531414A (ja) | 2017-08-14 | 2020-11-05 | エムイーアイ ファーマ，インク． | 併用療法 |
| EP3684366A4 (en) * | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES OF THE LATEST |
| US11709164B2 (en) | 2017-10-26 | 2023-07-25 | National University Of Singapore | Approach for universal monitoring of minimal residual disease in acute myeloid leukemia |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US20210196725A1 (en) * | 2018-08-14 | 2021-07-01 | Mei Pharma, Inc. | Treatment of relapsed follicular lymphoma |
| EP3848371A4 (en) * | 2018-09-07 | 2022-06-08 | Medshine Discovery Inc. | TRICYCLIC FURAN-SUBSTITUTED PIPERIDONEE COMPOUND |
| AU2019351811B2 (en) * | 2018-10-01 | 2025-01-02 | Celgene Corporation | Combination therapy for the treatment of cancer |
| MX2021005366A (es) | 2018-11-08 | 2021-09-10 | Juno Therapeutics Inc | Metodos y combinaciones para el tratamiento y modulacion de celulas t. |
| US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| SG11202110829YA (en) | 2019-04-05 | 2021-10-28 | Kymera Therapeutics Inc | Stat degraders and uses thereof |
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| EA039874B1 (ru) * | 2019-06-06 | 2022-03-22 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно) |
| KR20220103952A (ko) * | 2019-10-21 | 2022-07-25 | 셀진 코포레이션 | (s)-2-(2,6-디옥소피페리딘-3-일)-4-((2-플루오로-4-((3-모르폴리노아제티딘-1-일)메틸)벤질)아미노)이소인돌린-1,3-디온을 포함하는 제약 조성물 및 그의 사용 방법 |
| MX2022005524A (es) | 2019-11-07 | 2022-08-25 | Juno Therapeutics Inc | Combinacion de una terapia de celulas t y (s)-3-[4-(4-morfolin-4-i lmetil-benciloxi)-1-oxo-1,3-dihidro-isoindol-2-il]-piperidino-2,6 -diona. |
| CA3159978A1 (en) | 2019-12-02 | 2021-06-10 | Celgene Corporation | Therapy for the treatment of cancer |
| BR112022012410A2 (pt) | 2019-12-23 | 2022-08-30 | Kymera Therapeutics Inc | Degradadores smarca e usos dos mesmos |
| PH12022552458A1 (en) | 2020-03-19 | 2024-01-22 | Kymera Therapeutics Inc | Mdm2 degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| JP2023531512A (ja) * | 2020-06-25 | 2023-07-24 | セルジーン コーポレーション | 併用療法を用いて癌を治療するための方法 |
| EP4217352A4 (en) | 2020-09-23 | 2024-04-10 | St. Jude Children's Research Hospital, Inc. | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
| TW202241891A (zh) | 2020-12-30 | 2022-11-01 | 美商凱麥拉醫療公司 | Irak降解劑及其用途 |
| JP2024506656A (ja) | 2021-02-15 | 2024-02-14 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその使用 |
| US12097261B2 (en) | 2021-05-07 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
| WO2023076556A1 (en) | 2021-10-29 | 2023-05-04 | Kymera Therapeutics, Inc. | Irak4 degraders and synthesis thereof |
| JP2025504059A (ja) | 2022-01-31 | 2025-02-06 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋデグレーダー及びその使用 |
| WO2024015618A2 (en) * | 2022-07-15 | 2024-01-18 | St. Jude Children's Research Hospital, Inc. | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein |
| WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025120113A1 (en) | 2023-12-08 | 2025-06-12 | Celgene Corporation | Therapy for the treatment of multiple myeloma |
| WO2025195464A1 (zh) * | 2024-03-21 | 2025-09-25 | 上海惠康济民生物医药技术有限公司 | 取代的异吲哚啉类化合物、制备方法、药物组合物及应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| AU1325102A (en) | 2000-10-16 | 2002-04-29 | Phylos Inc | Protein scaffolds for antibody mimics and other binding proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| PT1390535E (pt) | 2001-04-26 | 2010-10-04 | Amgen Mountain View Inc | Bibliotecas combinatórias de domínios monoméricos |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| WO2006055689A2 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US20080051379A1 (en) | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
| EP2142534B1 (en) * | 2007-03-20 | 2016-08-10 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| US20120134969A1 (en) | 2009-05-25 | 2012-05-31 | Hiroshi Handa | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| SG10201501062SA (en) * | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| EP2544687A1 (en) * | 2010-03-12 | 2013-01-16 | Celgene Corporation | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| CA2829593A1 (en) * | 2011-03-11 | 2012-09-20 | Celgene Corporation | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases |
-
2013
- 2013-08-08 EP EP13751007.9A patent/EP2882442B1/en active Active
- 2013-08-08 SI SI201331908T patent/SI2882442T1/sl unknown
- 2013-08-08 TW TW102128576A patent/TWI653977B/zh active
- 2013-08-08 SG SG11201500998QA patent/SG11201500998QA/en unknown
- 2013-08-08 RS RS20210904A patent/RS62201B1/sr unknown
- 2013-08-08 IL IL288506A patent/IL288506B2/en unknown
- 2013-08-08 WO PCT/US2013/054055 patent/WO2014025960A1/en not_active Ceased
- 2013-08-08 BR BR112015002285-5A patent/BR112015002285B1/pt active IP Right Grant
- 2013-08-08 US US13/962,776 patent/US20140045843A1/en not_active Abandoned
- 2013-08-08 IN IN886DEN2015 patent/IN2015DN00886A/en unknown
- 2013-08-08 KR KR1020157006019A patent/KR102146848B1/ko active Active
- 2013-08-08 AU AU2013299627A patent/AU2013299627C1/en active Active
- 2013-08-08 JP JP2015526690A patent/JP6347782B2/ja active Active
- 2013-08-08 CA CA2881116A patent/CA2881116C/en active Active
- 2013-08-08 CN CN201380052496.0A patent/CN104837491A/zh active Pending
- 2013-08-08 PT PT137510079T patent/PT2882442T/pt unknown
- 2013-08-08 CN CN201711401933.1A patent/CN108245518B/zh active Active
- 2013-08-08 TW TW107117959A patent/TWI723266B/zh active
- 2013-08-08 HR HRP20211243TT patent/HRP20211243T1/hr unknown
- 2013-08-08 KR KR1020207023283A patent/KR102266510B1/ko active Active
- 2013-08-08 KR KR1020217018115A patent/KR102414005B1/ko active Active
- 2013-08-08 ES ES13751007T patent/ES2881220T3/es active Active
- 2013-08-08 NZ NZ628078A patent/NZ628078A/en unknown
- 2013-08-08 SG SG10202108516PA patent/SG10202108516PA/en unknown
- 2013-08-08 EP EP21177385.8A patent/EP3949968A1/en active Pending
- 2013-08-08 SM SM20210457T patent/SMT202100457T1/it unknown
- 2013-08-08 LT LTEPPCT/US2013/054055T patent/LT2882442T/lt unknown
- 2013-08-08 PL PL13751007T patent/PL2882442T3/pl unknown
- 2013-08-08 DK DK13751007.9T patent/DK2882442T3/da active
- 2013-08-08 CN CN202110938460.9A patent/CN114344307A/zh active Pending
- 2013-08-08 UA UAA201501971A patent/UA116544C2/uk unknown
- 2013-08-08 SG SG10201701057SA patent/SG10201701057SA/en unknown
- 2013-08-08 MX MX2015001775A patent/MX367869B/es active IP Right Grant
- 2013-08-08 HU HUE13751007A patent/HUE056127T2/hu unknown
- 2013-08-08 CN CN202110936758.6A patent/CN114366746A/zh active Pending
- 2013-08-08 EA EA201590345A patent/EA029485B1/ru not_active IP Right Cessation
-
2015
- 2015-01-26 ZA ZA2015/00564A patent/ZA201500564B/en unknown
- 2015-01-29 IL IL237013A patent/IL237013B/en active IP Right Grant
- 2015-01-30 PH PH12015500212A patent/PH12015500212A1/en unknown
- 2015-02-06 NI NI201500012A patent/NI201500012A/es unknown
-
2016
- 2016-05-13 US US15/154,838 patent/US20160256468A1/en not_active Abandoned
-
2018
- 2018-02-02 JP JP2018017168A patent/JP2018100276A/ja not_active Withdrawn
-
2019
- 2019-08-01 US US16/529,233 patent/US20190388429A1/en not_active Abandoned
-
2020
- 2020-07-27 IL IL276319A patent/IL276319B/en unknown
-
2021
- 2021-07-16 CY CY20211100645T patent/CY1124622T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018100276A5 (OSRAM) | ||
| JP2018012698A5 (OSRAM) | ||
| JP2023113641A5 (OSRAM) | ||
| JP2023134519A5 (OSRAM) | ||
| JP2024037765A5 (OSRAM) | ||
| JP2020010717A5 (OSRAM) | ||
| HUE066810T2 (hu) | Stabilizált fluorolefin kompozíciók és eljárás elõállításukra, tárolásukra és felhasználásukra | |
| JP2021502979A5 (OSRAM) | ||
| JP2019142968A5 (OSRAM) | ||
| JP2017214405A5 (OSRAM) | ||
| JP2014098143A5 (OSRAM) | ||
| WO2018081502A8 (en) | Synthetic bacteriophages and bacteriophage compositions | |
| JP2017137500A5 (OSRAM) | ||
| JP2018533683A5 (OSRAM) | ||
| JP2018064407A5 (OSRAM) | ||
| JP2017537928A5 (OSRAM) | ||
| JP2018507673A5 (OSRAM) | ||
| JP2020528637A5 (OSRAM) | ||
| JP2015186128A5 (OSRAM) | ||
| JP2017211493A5 (ja) | 露光装置、および、物品の製造方法 | |
| JP2023103231A5 (OSRAM) | ||
| JP2023139025A5 (OSRAM) | ||
| JP2016540026A5 (OSRAM) | ||
| JP2016540019A5 (OSRAM) | ||
| IL262747A (en) | Anti-kv1.3 antibodies, methods for their production and use |